Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Medical management of brain tumors and the sequelae of treatment.

Literature DB >> 25358508

Medical management of brain tumors and the sequelae of treatment.

David Schiff¹, Eudocia Q Lee¹, Lakshmi Nayak¹, Andrew D Norden¹, David A Reardon¹, Patrick Y Wen¹.

Abstract

Patients with malignant brain tumors are prone to complications that negatively impact their quality of life and sometimes their overall survival as well. Tumors may directly provoke seizures, hypercoagulable states with resultant venous thromboembolism, and mood and cognitive disorders. Antitumor treatments and supportive therapies also produce side effects. In this review, we discuss major aspects of supportive care for patients with malignant brain tumors, with particular attention to management of seizures, venous thromboembolism, corticosteroids and their complications, chemotherapy including bevacizumab, and fatigue, mood, and cognitive dysfunction.

Entities: Chemical Disease Species

Keywords: bevacizumab; brain tumor; chemotherapy; cognition; complications; corticosteroids; fatigue; mood; seizure; symptom management; vasogenic edema; venous thromboembolism

Mesh：

Substances：

Year: 2014 PMID： 25358508 PMCID： PMC4483077 DOI： 10.1093/neuonc/nou304

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

203 in total

1. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.

Authors: Xing Gong; Philip H Schwartz; Mark E Linskey; Daniela A Bota
Journal: Neurology Date: 2011-02-23 Impact factor: 9.910

Review 2. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management.

Authors: Melanie S M van Breemen; Erik B Wilms; Charles J Vecht
Journal: Lancet Neurol Date: 2007-05 Impact factor: 44.182

3. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors: Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544

4. A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245

5. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases.

Authors: Achala Bhaskara; Cathy Eng
Journal: Clin Colorectal Cancer Date: 2008-01 Impact factor: 4.481

6. Bevacizumab for recurrent ependymoma.

Authors: R M Green; T F Cloughesy; R Stupp; L M DeAngelis; E A Woyshner; D E Ney; A B Lassman
Journal: Neurology Date: 2009-11-17 Impact factor: 9.910

Review 7. Decreased phenytoin levels in patients receiving chemotherapy.

Authors: S A Grossman; V R Sheidler; M R Gilbert
Journal: Am J Med Date: 1989-11 Impact factor: 4.965

Review 8. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors: Timothy C Ryken; Michael McDermott; Paula D Robinson; Mario Ammirati; David W Andrews; Anthony L Asher; Stuart H Burri; Charles S Cobbs; Laurie E Gaspar; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Steven N Kalkanis
Journal: J Neurooncol Date: 2009-12-03 Impact factor: 4.130

9. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors.

Authors: Anuj K Mahindra; Stuart A Grossman
Journal: J Neurooncol Date: 2003-07 Impact factor: 4.506

Review 10. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy.

Authors: Tomas Kazda; Radim Jancalek; Petr Pospisil; Ondrej Sevela; Tomas Prochazka; Miroslav Vrzal; Petr Burkon; Marek Slavik; Ludmila Hynkova; Pavel Slampa; Nadia N Laack
Journal: Radiat Oncol Date: 2014-06-16 Impact factor: 3.481

39 in total

Review 1. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300

2. Dexamethasone-related adrenal insufficiency in patients with brain and skull base tumours.

Authors: H Benghiat; P Sanghera; D Stange; P Nightingale; A Hartley; M W O'Reilly; N Nundall; H Currie; M Ali; G Cruickshank; D Spooner; A Toogood
Journal: Support Care Cancer Date: 2018-06-01 Impact factor: 3.603

3. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.

Authors: Eudocia Q Lee; Alona Muzikansky; Jan Drappatz; Santosh Kesari; Eric T Wong; Camilo E Fadul; David A Reardon; Andrew D Norden; Lakshmi Nayak; Mikael L Rinne; Brian M Alexander; Nils D Arvold; Lisa Doherty; Jennifer Stefanik; Debra LaFrankie; Sandra F Ruland; Julee Pulverenti; Katrina H Smith; Sarah C Gaffey; Samantha Hammond; Patrick Y Wen
Journal: Neuro Oncol Date: 2016-02-21 Impact factor: 12.300

Review 4. Late effects of cancer treatment: consequences for long-term brain cancer survivors.

Authors: Montse Alemany; Roser Velasco; Marta Simó; Jordi Bruna
Journal: Neurooncol Pract Date: 2020-07-16

5. Antiangiogenic treatment of meningiomas.

Authors: Matthias Preusser; Christine Marosi
Journal: Curr Treat Options Neurol Date: 2015-07 Impact factor: 3.598

6. Nanomedicine for Spontaneous Brain Tumors: A Companion Clinical Trial.

Authors: Hamed Arami; Chirag B Patel; Steven J Madsen; Peter J Dickinson; Ryan M Davis; Yitian Zeng; Beverly K Sturges; Kevin D Woolard; Frezghi G Habte; Demir Akin; Robert Sinclair; Sanjiv S Gambhir
Journal: ACS Nano Date: 2019-02-04 Impact factor: 15.881

7. Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory.

Authors: Yang Liu; Pakawat Chongsathidkiet; Bridget M Crawford; Ren Odion; Cosette A Dechant; Hanna R Kemeny; Xiuyu Cui; Paolo F Maccarini; Christopher D Lascola; Peter E Fecci; Tuan Vo-Dinh
Journal: Immunotherapy Date: 2019-09-18 Impact factor: 4.196